Drug Trial Radar · NCT06031844
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 16, 2023
Primary completion
Dec 17, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 24 people with known heart disease and an elevated marker of inflammation, hsCRP.
Conditions
- Coronary Heart Disease
Interventions
DFV890Drug
Oral film-coated tablets of DFV890 once daily
DFV890 PlaceboDrug
Oral film-coated tablets of DFV890 placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
- Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax ModelTime frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Valley Clinical Trials
Northridge, California
Excel Medical Clinical Trials LLC
Boca Raton, Florida
UF Health Science Center
Jacksonville, Florida
Triad Clinical Trials LLC
Greensboro, North Carolina
Monument Health Clinical Research
Rapid City, South Dakota
Universal Research Group LLC
Tacoma, Washington
Novartis Investigative Site
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.